December 1, 2025Open Access

Efficacy of artemether-lumefantrine, dihydroartemisinin-piperaquine, and artesunate-pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso, 2020–2021

RKRene KindaCentre National de Recherche et de Formation sur le Paludisme ASAladari SagnonCentre National de Recherche et de Formation sur le Paludisme SSSalif SombiéUniversité Joseph Ki-Zerbo

Key Points

Efficacy of artemether-lumefantrine treatment was found to be low, with 50-33% of children returning with repeat infection.
PCR-corrected efficacy of AL treatment was at or below 90%, indicating concerns for malaria management.
First-line therapy alternatives like AS-PYR and DP showed low rates of recurrent parasitaemia, suggesting effective options.
This highlights the urgent need to preserve lumefantrine for future use and optimize malaria treatment approaches.

Abstract

Continued low uncorrected efficacy of AL was observed in all sites, with one half to one third of children returning to the clinic with repeat infection within 28 days. PCR-corrected efficacy was at or below 90% for AL. AS-PYR and DP were associated with low rates of recurrent parasitaemia suggesting a potential for implementing a multiple first-line therapy approach with non-AL ACT. This approach will allow to preserve future use of lumefantrine and improve patient outcomes.

AI से पूछें

Bookmark

View Full Paper

Cite This Study

Kinda et al. (Mon,) studied this question.

synapsesocial.com/papers/694028c12d562116f2900522 https://doi.org/https://doi.org/10.1186/s12936-025-05693-z

AI से पूछें

Bookmark

View Full Paper